PharmaPath and Innovis Pharma are pleased to announce the successful completion of the acquisition of Innovis Pharma by PharmaPath, following an initial agreement signed in December 2025.

This strategic milestone, sets new standards for both companies, marking the creation of a new fully integrated Greek pharmaceutical group with more than 450 employees, combining advanced expertise in research and development, strong manufacturing capabilities and commercial excellence.

PharmaPath, based in Athens, Greece is a rapidly growing pharmaceutical company with robust R&D activity and strong out-license focus, supplying its partners in Greece and in more than 120 countries worldwide with high quality generic medicines. Innovis Pharma, also based in Athens, Greece is among the leading Greek pharmaceutical companies, with an extensive and diversified portfolio that includes branded and generic medicines, medical devices, OTC products, food supplements, and cosmetics.

By combining scientific know-how, pharmaceutical innovation, and commercial excellence, the two companies, under the new structure, will continue to develop and deliver high- quality products that respond to evolving healthcare needs and expand across additional therapeutic categories.

PharmaPath Group’s strategic plan focuses on the further development and strengthening of both companies’ presence, position, and momentum in the Greek and global market through new agreements, partnerships, and further investments. At the same time, with uninterrupted patient access to reliable and high-quality therapies as a central priority, the newly founded Group is expected to serve as a reference point within the Greek pharmaceutical ecosystem, contributing meaningfully to the sustainability and efficiency of healthcare systems, through a dynamic investment program with strong social footprint and long-term growth trajectory.